NASDAQ:BFRI Biofrontera (BFRI) Stock Price, News & Analysis $1.00 -0.04 (-3.37%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$1.06 +0.06 (+5.87%) As of 08/4/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biofrontera Stock (NASDAQ:BFRI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biofrontera alerts:Sign Up Key Stats Today's Range$1.00▼$1.1150-Day Range$0.57▼$1.1152-Week Range$0.54▼$2.22Volume76,441 shsAverage Volume180,209 shsMarket Capitalization$10.19 millionP/E RatioN/ADividend YieldN/APrice Target$2.75Consensus RatingBuy Company Overview Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Read More Biofrontera Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreBFRI MarketRank™: Biofrontera scored higher than 31% of companies evaluated by MarketBeat, and ranked 1539th out of 1,836 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiofrontera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiofrontera has only been the subject of 1 research reports in the past 90 days.Read more about Biofrontera's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biofrontera are expected to grow in the coming year, from ($3.01) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biofrontera is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biofrontera is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiofrontera has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biofrontera's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.58% of the float of Biofrontera has been sold short.Short Interest Ratio / Days to CoverBiofrontera has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biofrontera has recently increased by 22.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiofrontera does not currently pay a dividend.Dividend GrowthBiofrontera does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.58% of the float of Biofrontera has been sold short.Short Interest Ratio / Days to CoverBiofrontera has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biofrontera has recently increased by 22.60%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Biofrontera this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for BFRI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biofrontera insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.20% of the stock of Biofrontera is held by insiders.Percentage Held by InstitutionsOnly 10.08% of the stock of Biofrontera is held by institutions.Read more about Biofrontera's insider trading history. Receive BFRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Email Address BFRI Stock News HeadlinesBiofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025August 4 at 2:00 PM | globenewswire.comBiofrontera restructures relationship with Biofrontera AG, backed by $11M investment - Seeking AlphaJuly 2, 2025 | seekingalpha.comMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia. | The Oxford Club (Ad)Biofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million Investment - Seeking AlphaJuly 2, 2025 | seekingalpha.comBiofrontera Restructures U.S. Rights with $11M InvestmentJune 30, 2025 | tipranks.comBiofrontera restructures relationship with Biofrontera AG, backed by $11M investmentJune 30, 2025 | msn.comBiofrontera Inc. Announces Major Restructuring of Relationship With Biofrontera AG Backed By $11 Million InvestmentJune 30, 2025 | globenewswire.comBIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AGJune 11, 2025 | globenewswire.comSee More Headlines BFRI Stock Analysis - Frequently Asked Questions How have BFRI shares performed this year? Biofrontera's stock was trading at $1.09 on January 1st, 2025. Since then, BFRI shares have decreased by 7.8% and is now trading at $1.0050. How were Biofrontera's earnings last quarter? Biofrontera Inc. (NASDAQ:BFRI) announced its quarterly earnings results on Thursday, May, 15th. The company reported ($0.47) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.33. The company had revenue of $8.59 million for the quarter, compared to the consensus estimate of $10.55 million. Biofrontera had a negative trailing twelve-month return on equity of 305.13% and a negative net margin of 30.33%. Read the conference call transcript. When did Biofrontera's stock split? Shares of Biofrontera reverse split on the morning of Wednesday, July 5th 2023.The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Biofrontera IPO? Biofrontera (BFRI) raised $19 million in an IPO on Friday, October 29th 2021. The company issued 3,100,000 shares at $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company acted as the underwriters for the IPO. Who are Biofrontera's major shareholders? Top institutional investors of Biofrontera include AIGH Capital Management LLC (9.61%). How do I buy shares of Biofrontera? Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biofrontera own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biofrontera investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NVIDIA (NVDA), NIO (NIO) and Meta Platforms (META). Company Calendar Last Earnings5/15/2025Today8/04/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BFRI CIK1858685 Webwww.biofrontera-us.com Phone781-245-1325FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Price Target for Biofrontera$2.75 High Price Target$2.75 Low Price Target$2.75 Potential Upside/Downside+173.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($2.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.76 million Net Margins-30.33% Pretax Margin-30.28% Return on Equity-305.13% Return on Assets-82.67% Debt Debt-to-Equity Ratio8.99 Current Ratio1.40 Quick Ratio0.80 Sales & Book Value Annual Sales$37.32 million Price / Sales0.27 Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book1.76Miscellaneous Outstanding Shares10,140,000Free Float10,017,000Market Cap$10.19 million OptionableNo Data Beta0.50 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:BFRI) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biofrontera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.